Univariate analysis of relapse probability in the 450 patients with malignant disease
| . | Univariate analysis . | ||||
|---|---|---|---|---|---|
| Number of cases . | Events . | Probability, % . | (95% CI) . | P . | |
| Patient age | |||||
| Younger than 5 y | 110 | 30 | 28 | (20 -37) | NS |
| 5-10 y | 174 | 51 | 34 | (26 -41) | |
| 10-15 y | 125 | 32 | 29 | (20 -38) | |
| 15 y or older | 41 | 14 | 41 | (22 -60) | |
| Donor age | |||||
| Younger than 5 y | 81 | 23 | 31 | (20 -42) | NS |
| 5-10 y | 95 | 24 | 27 | (17 -36) | |
| 10-15 y | 64 | 18 | 33 | (19 -46) | |
| 15-20 y | 55 | 14 | 28 | (15 -40) | |
| 20-30 y | 69 | 22 | 34 | (23 -46) | |
| 30-40 y | 56 | 17 | 37 | (21 -52) | |
| 40 y or older | 30 | 9 | 44 | (15 -72) | |
| Sex | |||||
| Female donor and male recipient | 103 | 20 | 21 | (13 -29) | .0706 |
| Other | 320 | 90 | 32 | (26 -38) | |
| Diagnosis | |||||
| ALL | 268 | 87 | 35 | (29 -41) | NS |
| AML | 99 | 24 | 31 | (19 -42) | |
| MDS | 36 | 8 | 25 | (10 -40) | |
| CML | 28 | 3 | 18 | (0 -39) | |
| Lymphoma | 19 | 5 | 28 | (7 -49) | |
| Disease phase | |||||
| Early | 285 | 66 | 26 | (21 -32) | .0003 |
| Advanced | 165 | 61 | 42 | (34 -51) | |
| Donor | |||||
| HLA-identical family | 306 | 85 | 30 | (25 -36) | NS |
| Other donor | 144 | 42 | 36 | (26 -46) | |
| Stem cell source | |||||
| Bone marrow + peripheral blood | 434 | 121 | 31 | (26 -36) | NS |
| Cord blood | 16 | 6 | 52 | (19 -85) | |
| GVHD prophylaxis | |||||
| Cs-A + MTX + ALG or mAb | 81 | 25 | 34 | (23 -45) | NS |
| Other prophylaxis | 369 | 102 | 31 | (26 -36) | |
| Conditioning regimen | |||||
| Chemotherapy based | 148 | 41 | 33 | (24 -43) | NS |
| TBI based | 302 | 86 | 31 | (26 -37) | |
| Acute GVHD | |||||
| 0-I | 223 | 77 | 38 | (31 -45) | .0005 |
| II-IV | 227 | 49 | 25 | (18 -31) | |
| Chronic GVHD | |||||
| Absent | 308 | 107 | 39 | (33 -45) | .0001 |
| Present | 142 | 20 | 16 | (9 -22) | |
| Chronic GVHD | |||||
| Absent | 308 | 107 | 39 | (33 -45) | .0001 |
| Limited | 89 | 16 | 20 | (11 -28) | |
| Extensive | 53 | 4 | 10 | (0 -19) | |
| . | Univariate analysis . | ||||
|---|---|---|---|---|---|
| Number of cases . | Events . | Probability, % . | (95% CI) . | P . | |
| Patient age | |||||
| Younger than 5 y | 110 | 30 | 28 | (20 -37) | NS |
| 5-10 y | 174 | 51 | 34 | (26 -41) | |
| 10-15 y | 125 | 32 | 29 | (20 -38) | |
| 15 y or older | 41 | 14 | 41 | (22 -60) | |
| Donor age | |||||
| Younger than 5 y | 81 | 23 | 31 | (20 -42) | NS |
| 5-10 y | 95 | 24 | 27 | (17 -36) | |
| 10-15 y | 64 | 18 | 33 | (19 -46) | |
| 15-20 y | 55 | 14 | 28 | (15 -40) | |
| 20-30 y | 69 | 22 | 34 | (23 -46) | |
| 30-40 y | 56 | 17 | 37 | (21 -52) | |
| 40 y or older | 30 | 9 | 44 | (15 -72) | |
| Sex | |||||
| Female donor and male recipient | 103 | 20 | 21 | (13 -29) | .0706 |
| Other | 320 | 90 | 32 | (26 -38) | |
| Diagnosis | |||||
| ALL | 268 | 87 | 35 | (29 -41) | NS |
| AML | 99 | 24 | 31 | (19 -42) | |
| MDS | 36 | 8 | 25 | (10 -40) | |
| CML | 28 | 3 | 18 | (0 -39) | |
| Lymphoma | 19 | 5 | 28 | (7 -49) | |
| Disease phase | |||||
| Early | 285 | 66 | 26 | (21 -32) | .0003 |
| Advanced | 165 | 61 | 42 | (34 -51) | |
| Donor | |||||
| HLA-identical family | 306 | 85 | 30 | (25 -36) | NS |
| Other donor | 144 | 42 | 36 | (26 -46) | |
| Stem cell source | |||||
| Bone marrow + peripheral blood | 434 | 121 | 31 | (26 -36) | NS |
| Cord blood | 16 | 6 | 52 | (19 -85) | |
| GVHD prophylaxis | |||||
| Cs-A + MTX + ALG or mAb | 81 | 25 | 34 | (23 -45) | NS |
| Other prophylaxis | 369 | 102 | 31 | (26 -36) | |
| Conditioning regimen | |||||
| Chemotherapy based | 148 | 41 | 33 | (24 -43) | NS |
| TBI based | 302 | 86 | 31 | (26 -37) | |
| Acute GVHD | |||||
| 0-I | 223 | 77 | 38 | (31 -45) | .0005 |
| II-IV | 227 | 49 | 25 | (18 -31) | |
| Chronic GVHD | |||||
| Absent | 308 | 107 | 39 | (33 -45) | .0001 |
| Present | 142 | 20 | 16 | (9 -22) | |
| Chronic GVHD | |||||
| Absent | 308 | 107 | 39 | (33 -45) | .0001 |
| Limited | 89 | 16 | 20 | (11 -28) | |
| Extensive | 53 | 4 | 10 | (0 -19) | |